表紙
市場調查報告書

全球蛋白質治療藥市場:2017∼2021年

Global Protein Therapeutics Market 2020-2024

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 345849
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
全球蛋白質治療藥市場:2017∼2021年 Global Protein Therapeutics Market 2020-2024
出版日期: 2020年04月23日內容資訊: 英文 120 Pages
簡介

治療性蛋白質,廣泛使用作為蛋白質缺乏症等各種疾病、癌症、類風濕性關節炎等的治療。全球蛋白質治療藥市場,預計以2017∼2021年以7.86%的年複合成長率擴大。

本報告提供全球蛋白質治療藥市場相關調查,市場趨勢與課題,各產品,各治療領域,各蛋白質功能,及各地區趨勢,至2021年的市場成長預測,主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 市場情況

  • 市場概要
  • 波特的五力分析

第6章 各產品市場區隔

  • 單株抗體
  • 胰島素注射液
  • 凝血因子
  • EPO
  • 人體生長荷爾蒙

第7章 各治療領域市場區隔

  • 代謝性疾病及內分泌疾病
  • 造血
  • 不孕症
  • 癌症
  • 自體免疫疾病
  • 感染疾病
  • 蛋白質疫苗

第8章 各蛋白質功能市場市場區隔

  • 酵素活性及控制活性
  • 特殊標的活性
  • 疫苗
  • 蛋白質診斷

第9章 各地區市場區隔

  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區

第10章 推動市場的要素

第11章 促進要素的影響

第12章 市場課題

第13章 促進要素與課題的影響

第14章 市場趨勢

第15章 供應商環境

  • 競爭模式
  • 市場佔有率分析:2016年
  • 其他值得注意的供應商

第16章 主要供應商分析

  • F. Hoffmann-La Roche
  • Novo Nordisk
  • Amgen
  • AbbVie
  • Johnson & Johnson
  • Merck

第17章 附錄

第18章 關於Technavio

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR43438

Technavio has been monitoring the protein therapeutics market and it is poised to grow by $ 82.47 bn during 2020-2024 progressing at a CAGR of 7% during the forecast period. Our reports on protein therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increased demand for mAbs and the availability of favorable reimbursement policies.

The protein therapeutics market analysis includes product segment and geographic landscape.

Technavio's ‘ protein therapeutics market ’ is segmented as below:

By Product:

  • mAbs
  • Human insulin
  • Erythropoeitin
  • Clotting factors
  • Others

By Geographic Landscape:

  • North America
  • Europe
  • APAC
  • South America
  • MEA

This study identifies the development of novel therapies using innovative technologies as one of the prime reasons driving the protein therapeutics market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our protein therapeutics market covers the following areas:

  • Protein therapeutics market sizing
  • Protein therapeutics market forecast
  • Protein therapeutics market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading protein therapeutics market vendors that include AbbVie Inc., Amgen Inc., AstraZeneca Plc, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co. Inc., Novo Nordisk AS, Pfizer Inc., and Sanofi. Also, the protein therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five Forces Summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Product

  • Market segments
  • Comparison by Product
  • mAbs - Market size and forecast 2019-2024
  • Human insulin - Market size and forecast 2019-2024
  • Erythropoeitin - Market size and forecast 2019-2024
  • Clotting factors - Market size and forecast 2019-2024
  • Others - Market size and forecast 2019-2024
  • Market opportunity by Product

Market segmentation by Therapy Area

  • Market segments
  • Metabolic and endocrine disorders
  • Hematopoiesis
  • Fertility
  • Cancer
  • Autoimmune diseases
  • Infectious diseases
  • Protein vaccine

Market segmentation by Protein Function

  • Market segments
  • Enzymatic and regulatory activity
  • Special targeting activity
  • Vaccines
  • Protein diagnostics

Customer Landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • APAC - Market size and forecast 2019-2024
  • South America - Market size and forecast 2019-2024
  • MEA - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novo Nordisk AS
  • Pfizer Inc.
  • Sanofi

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2019 - 2024 ($ billion)
  • 13: Global market: Year-over-year growth 2019 - 2024 (%)
  • 14: Five forces analysis 2019 & 2024
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2019
  • 21: Product - Market share 2019-2024 (%)
  • 22: Comparison by Product
  • 23: mAbs - Market size and forecast 2019-2024 ($ billion)
  • 24: mAbs - Year-over-year growth 2019-2024 (%)
  • 25: Human insulin - Market size and forecast 2019-2024 ($ billion)
  • 26: Human insulin - Year-over-year growth 2019-2024 (%)
  • 27: Erythropoeitin - Market size and forecast 2019-2024 ($ billion)
  • 28: Erythropoeitin - Year-over-year growth 2019-2024 (%)
  • 29: Clotting factors - Market size and forecast 2019-2024 ($ billion)
  • 30: Clotting factors - Year-over-year growth 2019-2024 (%)
  • 31: Others - Market size and forecast 2019-2024 ($ billion)
  • 32: Others - Year-over-year growth 2019-2024 (%)
  • 33: Market opportunity by Product
  • 34: Customer landscape
  • 35: Market share by geography 2019-2024 (%)
  • 36: Geographic comparison
  • 37: North America - Market size and forecast 2019-2024 ($ billion)
  • 38: North America - Year-over-year growth 2019-2024 (%)
  • 39: Europe - Market size and forecast 2019-2024 ($ billion)
  • 40: Europe - Year-over-year growth 2019-2024 (%)
  • 41: APAC - Market size and forecast 2019-2024 ($ billion)
  • 42: APAC - Year-over-year growth 2019-2024 (%)
  • 43: South America - Market size and forecast 2019-2024 ($ billion)
  • 44: South America - Year-over-year growth 2019-2024 (%)
  • 45: MEA - Market size and forecast 2019-2024 ($ billion)
  • 46: MEA - Year-over-year growth 2019-2024 (%)
  • 47: Key leading countries
  • 48: Market opportunity by geography ($ billion)
  • 49: Impact of drivers and challenges
  • 50: Vendor landscape
  • 51: Landscape disruption
  • 52: Industry risks
  • 53: Vendors covered
  • 54: Market positioning of vendors
  • 55: AbbVie Inc. - Overview
  • 56: AbbVie Inc. - Business segments
  • 57: AbbVie Inc. - Key offerings
  • 58: AbbVie Inc. - Key customers
  • 59: AbbVie Inc. - Segment focus
  • 60: Amgen Inc. - Overview
  • 61: Amgen Inc. - Business segments
  • 62: Amgen Inc. - Key offerings
  • 63: Amgen Inc. - Key customers
  • 64: Amgen Inc. - Segment focus
  • 65: AstraZeneca Plc - Overview
  • 66: AstraZeneca Plc - Business segments
  • 67: AstraZeneca Plc - Key offerings
  • 68: AstraZeneca Plc - Key customers
  • 69: AstraZeneca Plc - Segment focus
  • 70: Eli Lilly and Co. - Overview
  • 71: Eli Lilly and Co. - Business segments
  • 72: Eli Lilly and Co. - Key offerings
  • 73: Eli Lilly and Co. - Key customers
  • 74: Eli Lilly and Co. - Segment focus
  • 75: F. Hoffmann-La Roche Ltd. - Overview
  • 76: F. Hoffmann-La Roche Ltd. - Business segments
  • 77: F. Hoffmann-La Roche Ltd. - Key offerings
  • 78: F. Hoffmann-La Roche Ltd. - Key customers
  • 79: F. Hoffmann-La Roche Ltd. - Segment focus
  • 80: Johnson & Johnson - Overview
  • 81: Johnson & Johnson - Business segments
  • 82: Johnson & Johnson - Key offerings
  • 83: Johnson & Johnson - Key customers
  • 84: Johnson & Johnson - Segment focus
  • 85: Merck & Co. Inc. - Overview
  • 86: Merck & Co. Inc. - Business segments
  • 87: Merck & Co. Inc. - Key offerings
  • 88: Merck & Co. Inc. - Key customers
  • 89: Merck & Co. Inc. - Segment focus
  • 90: Novo Nordisk AS - Overview
  • 91: Novo Nordisk AS - Business segments
  • 92: Novo Nordisk AS - Key offerings
  • 93: Novo Nordisk AS - Key customers
  • 94: Novo Nordisk AS - Segment focus
  • 95: Pfizer Inc. - Overview
  • 96: Pfizer Inc. - Business segments
  • 97: Pfizer Inc. - Key offerings
  • 98: Pfizer Inc. - Key customers
  • 99: Pfizer Inc. - Segment focus
  • 100: Sanofi - Overview
  • 101: Sanofi - Business segments
  • 102: Sanofi - Key offerings
  • 103: Sanofi - Key customers
  • 104: Sanofi - Segment focus
  • 105: Currency conversion rates for US$
  • 106: Research Methodology
  • 107: Validation techniques employed for market sizing
  • 108: Information sources
  • 109: List of abbreviations